Trial · NCT07898501
SVF Cellular Composition, Secretome, and Responses in Knee Osteoarthritis
NCT07898501, Recruiting, Yonsei University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SVF Cellular Composition, Secretome, and Responses in Knee Osteoarthritis. Trials, record NCT07898501. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898501
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SVF Cellular Composition, Secretome, and Responses in Knee Osteoarthritis
- NCT number
- NCT07898501
- Status
- Recruiting
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Yonsei University
- Conditions
- Osteoarthritis, Knee
- Interventions
- Autologous adipose-derived stromal vascular fraction intra-articular injection
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Red blood cell contamination of research-only SVF | Baseline (procedure day) | Red blood cell contamination proportion in research-only SVF. |
| Primary | Total nucleated cell count of research-only SVF | Baseline (procedure day) | Number of nucleated cells in research-only SVF. |
| Primary | MSC-like stromal progenitor cell composition | Baseline (procedure day) | Research-only SVF cells with the protocol phenotype CD73+, CD90+, CD146+/CD45-, CD31-. |
| Primary | CD34-positive adipose stromal progenitor cell composition | Baseline (procedure day) | Research-only SVF CD34+ adipose stromal progenitor cells. |
| Primary | Research-only SVF secretome analyte concentrations | Baseline (procedure day) | Individual concentrations of HGF, VEGF-A, IGF-1, IL-1β/IL-1F2, IL-1Ra/IL-1F3, IL-6, IL-10, PGE2, IL-8/CXCL8, MMP-3, MMP-13, and COMP. |
| Primary | Change from baseline in synovial fluid biomarker concentrations at 6 months | Immediately before injection and 6 months after injection | Paired change in each of the same 12 analytes listed in outcome 5. Each analyte is assessed individually. Six-month synovial fluid concentrations are recorded in pg/mL; paired measurements use the same units. |
| Secondary | Change from baseline in pain VAS at 6 months | Baseline and 6 months after injection | Activity-related knee pain VAS, 0-10; higher scores indicate greater pain. |
| Secondary | Change from baseline in WOMAC at 6 months | Baseline and 6 months after injection | WOMAC total score, 0-96, with pain (0-20), stiffness (0-8), and physical function (0-68) subscales. Higher scores indicate worse symptoms or disability. |
| Secondary | Change from baseline in KOOS at 6 months | Baseline and 6 months after injection | KOOS symptoms, pain, activities of daily living, sport/recreation, and knee-related quality-of-life subscales, each 0-100; higher scores indicate better status. Subscales are assessed separately. |
| Secondary | Change from baseline in IKDC subjective score at 6 months | Baseline and 6 months after injection | IKDC subjective score, 0-100; higher scores indicate better function and fewer symptoms. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898501
GET https://conductscience.org/api/trials/v1/NCT07898501/registered